/

KNSA

Kiniksa Pharmaceuticals InternaPre-market

79.24−0.54 −0.68%USD

NasdaqGS · as of Oct 12, 16:00 ET · 15m delay

Open

80.00

Prev close

79.78

Day range

78.8280.99

52-week range

35.2082.94

Volume

340.92K0.60×

Mkt cap

6.18B

P/E ttm

79.24

Fwd P/E

48.99

EPS ttm

1.00

Div yield

0.00%

Earnings

Jul 28, 2026

From 52w high

−4.46%

Price Chart

Yahoo Finance · delayed

KNSAOct 12, 2026O 80.00H 80.99L 78.82C 79.24−0.54 (−0.68%)Vol 340.90K

SMA 5077.60
SMA 20057.29

1Y change +109.13% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

KNSA Kiniksa Pharmaceuticals Interna · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +3.84%
1 month: +3.89%
3 months: +30.03%
6 months: +67.53%
Year to date: +92.10%
1 year: +109.13%

Valuation & ownership

Market cap: 6.18B
Enterprise value: 5.67B
P/E (ttm): 79.24
Forward P/E: 48.99
PEG ratio: —
Price / book: 9.45
Price / sales (ttm): 7.35
EV / EBITDA: 55.52
EPS (ttm): 1.00
EPS (forward): 1.62
Beta (5y monthly): 0.04
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 48.29M
Float: 39.86M
Short % of float: 9.45%
Short ratio (days): 6.69
Held by insiders: 3.51%
Held by institutions: 100.98%
Avg volume (3m): 569.71K
50-day average: 77.60
200-day average: 57.29
52-week change: +109.13%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 58.8
vs 50-day SMA: +2.12%
vs 200-day SMA: +38.32%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 3.34%
Realised vol (20d, ann.): 24.5%
From 52-week high: −4.46%
From 52-week low: +125.11%

ANR

Analyst Consensus

8 analysts

Consensus

Strong buy

1.13 on a 1 (strong buy) – 5 (sell) scale

Mean target

98.00

+23.67% implied

Low 87.00Median 98.50High 108.00

Recommendation trend

Now8 / 0 / 0
1m ago8 / 0 / 0

DES

About Kiniksa Pharmaceuticals Interna

Yahoo Finance profile

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 366
Headquarters: London, United Kingdom
Website: kiniksa.com
Officers: Mr. Sanjiv K. Patel CEO & Chairman of the Board
Mr. Mark A. Ragosa C.F.A. Executive VP & CFO
Mr. Ross Michael Moat Executive VP, COO & Principal Operating Officer
Dr. John F. Paolini FACC, M.D., Ph.D.

SEAS

Seasonality · KNSA

2018–2026 · monthly returns

Strongest month Nov +19.29%Weakest month Oct −10.83%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	6.5	1.3	8.2	11.7	-10.0	32.2	16.2	5.8	-5.1	6.2			+92.1%
2025	-0.9	3.5	9.5	21.4	1.4	1.1	9.4	10.7	15.9	-4.7	14.9	-3.0	+108.5%
2024	0.5	19.9	-6.7	-5.1	1.5	-1.8	42.5	0.5	-6.5	-9.6	-2.3	-10.4	+12.8%
2023	-3.5	-11.1	-16.3	-0.1	28.9	1.6	33.8	-8.5	0.8	-12.2	6.0	8.5	+17.1%
2022	-4.6	-8.8	-2.9	-6.1	-17.9	26.5	2.3	18.3	9.6	-11.1	47.4	-11.0	+27.3%
2021	11.4	4.5	-10.0	-11.1	-17.2	2.2	10.1	-17.9	-9.5	-8.8	11.8	1.3	−33.4%
2020	33.0	25.5	-16.1	28.9	4.6	22.1	-23.4	-9.5	-13.3	2.2	19.2	-5.3	+59.8%
2019	-37.7	2.6	0.6	-17.3	2.1	-11.2	-12.9	-25.2	-3.6	-17.2	51.1	3.8	−60.6%
2018						1.4	-19.4	57.5	15.7	-25.3	6.2	38.9	+64.2%

INSD

Insider Activity · KNSA

Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

1.63M shares

Sells, 6 months

636.7K shares

Net shares

+997K

Net change in insider shares

+57.30%

Date	Insider	Transaction	Shares	Value
Sep 2, 2026	Megna Michael ROfficer	Sale at price 80.30 per share.	4.6K	$369.38K
Aug 31, 2026	Megna Michael ROfficer	—	11.5K	—
Aug 31, 2026	Patel Sanjiv KChief Executive Officer	—	31.3K	—
Aug 31, 2026	Paolini John FOfficer	—	8.3K	—
Aug 31, 2026	Ragosa MarkChief Financial Officer	—	9.1K	—
Aug 31, 2026	Moat RossChief Operating Officer	—	8.3K	—
Aug 18, 2026	Quart Barry DDirector	Stock Gift at price 0.00 per share.	2.6K	—
Jul 30, 2026	Levy Richard SDirector	—	403	—
Jul 28, 2026	Cole Gordon BradleyDirector	Stock Gift at price 0.00 per share.	4.5K	—
Jul 28, 2026	Cole Gordon BradleyDirector	Sale at price 81.43 per share.	3.7K	$299.09K
Jul 14, 2026	Megna Michael ROfficer	Stock Award(Grant) at price 61.69 per share.	279	$17.21K
May 31, 2026	Patel Sanjiv KChief Executive Officer	—	900K	—
May 28, 2026	Baker Bros Advisors L.P.Unknown	Stock Award(Grant) at price 0.00 per share.	12.2K	—
May 28, 2026	Quart Barry DDirector	—	2.8K	—
May 28, 2026	Cole Gordon BradleyDirector	—	2.8K	—
May 28, 2026	Popovits Kimberly JDirector	—	2.8K	—
May 28, 2026	Malley Thomas RobertDirector	—	2.8K	—
May 28, 2026	Levy Richard SDirector	—	2.8K	—
May 28, 2026	Mccain Tracey LoreneDirector	—	2.8K	—
Apr 30, 2026	Patel Sanjiv KChief Executive Officer	Conversion of Exercise of derivative security at price 30.93 per share.	48.6K	$1.50M

KNSA

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

KNSA

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Kiniksa Pharmaceuticals Interna

Seasonality · KNSA

Insider Activity · KNSA

Congress Trades · KNSA

Congress Trades · KNSA

Insider Activity · KNSA

Seasonality · KNSA

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Kiniksa Pharmaceuticals Interna

Financial Snapshot

Earnings & Dividends

News